Phase 3 Breast Cancer Trial, Recruiting NCT02535221 Sponsor: Peking University Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT02535221
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 35 and 55 years old and have not yet gone through menopause (as determined by the research team at the time of joining)
  • People whose breast cancer has been confirmed by a tissue sample (biopsy) to be a primary invasive breast cancer
  • People whose cancer is at a specific stage — the tumour is larger than 2cm but has not spread to lymph nodes or other parts of the body, and breast-conserving surgery (removing only part of the breast) is not considered possible or would significantly affect the appearance of the breast
  • People whose cancer has been confirmed by lab testing to be hormone receptor-positive (meaning the cancer responds to oestrogen or progesterone, with more than 50% of cells showing this) and HER2-negative
  • People who have not received any previous treatment for their breast cancer
  • People who do not have another active tumour, an unstable serious health condition, or an uncontrolled infection
  • People for whom there are no medical reasons preventing the use of a type of hormone-blocking medication called a third-generation aromatase inhibitor (AI), LHRHa (a hormone therapy), or chemotherapy
  • People who are willing to take part voluntarily and have signed a consent form

Who may not be able to join:

  • People whose cancer has been confirmed by lab testing or imaging to have spread to other parts of the body (metastatic disease)
  • People who have a history of another type of cancer
  • People for whom there are medical reasons preventing the use of a third-generation aromatase inhibitor (AI), LHRHa, or chemotherapy
  • People who have serious heart or blood vessel disease, liver or kidney problems, blood disorders, or other health conditions that make chemotherapy unsafe or unsuitable
  • People for whom surgery is not possible — for example, due to risks with anaesthesia, a very large tumour, a tumour classified as T4, or cancer that has spread to the lymph nodes
  • People with psychological conditions, mental health disorders, social circumstances, or geographical situations that the research team considers unsuitable for participation
  • People who are currently taking part in, or have previously taken part in, another anti-cancer treatment trial
  • People who do not wish to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Peking University
Registry
ClinicalTrials.gov
Start date
29 July 2015
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ultrasound response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov